On October 13-14, 2026, members of approximately 25 Rockefeller University laboratories gathered at Windrose on Hudson in Ossining, NY, for the biennial Infectious Disease, Immunology, and Metabolism (IDIM) Retreat. Sponsored by the Stavros Niarchos Foundation Institute for Global Infectious Disease Research, the retreat brought researchers together in an informal setting to share recent work and […]
On March 24, 2026, The Rockefeller University convened its scientific community for the 4th Annual Symposium of the Stavros Niarchos Foundation (SNF) Institute for Global Infectious Disease Research. Held in Caspary Auditorium and Abby Reception Hall, the day-long event brought together investigators, trainees, and collaborators to showcase scientific advances and foster collaboration. Keynote Address Sharon […]
The Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller University is funding a new one-year joint project with The Hastings Center for Bioethics to address the persistent disparities in global access to new medical technologies. Advances in biological science and technology have drastically improved global health metrics, yet the COVID-19 pandemic starkly […]
A drug made from an antibody discovered and licensed by Rockefeller University in the US will be tested for production on a pharmaceutical scale at the Institute’s factory.
“A Clinical Cure for HBV? Identifying and Targeting Effective Immunity” Jody Baron, MD, PhDUniversity of California San Francisco
The 3rd Annual SNF Institute for Global Infectious Disease Research Symposium took place on the Rockefeller campus. Sixty four presentations were given by Rockefeller SNF Faculty and trainees. The institute kicked off its third year of funding with an exciting day of science and collaboration.
Recent advancements in HIV research are showing promising results. The RIO trial, led by Imperial College London, assessed the impact of two long-acting immune therapies known as broadly neutralizing antibodies (bNAbs) among 68 people living with HIV. The trial results revealed that three-quarters of participants who received the bNAbs were able to control the virus […]
Recent advancements in HIV research are bringing us closer to a “functional cure.” At the Conference on Retroviruses and Opportunistic Infections (CROI) 2025, Gilead Sciences presented groundbreaking data from its innovative HIV treatment portfolio. The new findings highlight a transformative portfolio and a rapidly advancing pipeline focused on expanding choices and enhancing outcomes for those […]
“Impairment of immunological and neurological synapses by respiratory viruses. Implications for vaccine design” Prof. Alexis KalergisFull Professor, Schools of Biological Sciences and Medicine, Pontificia Universidad Católica de ChileDoctor on Microbiology and Immunology, Albert Einstein College of Medicine, New York
